251 related articles for article (PubMed ID: 27906166)
1. Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.
D'Andrea E; Marzuillo C; De Vito C; Di Marco M; Pitini E; Vacchio MR; Villari P
Genet Med; 2016 Dec; 18(12):1171-1180. PubMed ID: 27906166
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
[TBL] [Abstract][Full Text] [Related]
3. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Whole Population BRCA Genetic Screening for Cancer Prevention in Israel.
Michaan N; Leshno M; Safra T; Sonnenblick A; Laskov I; Grisaru D
Cancer Prev Res (Phila); 2021 Apr; 14(4):455-462. PubMed ID: 33355193
[TBL] [Abstract][Full Text] [Related]
5. Familial communication and cascade testing among relatives of BRCA population screening participants.
Lieberman S; Lahad A; Tomer A; Koka S; BenUziyahu M; Raz A; Levy-Lahad E
Genet Med; 2018 Nov; 20(11):1446-1454. PubMed ID: 29595811
[TBL] [Abstract][Full Text] [Related]
6. Preventing future cancers by testing women with ovarian cancer for BRCA mutations.
Kwon JS; Daniels MS; Sun CC; Lu KH
J Clin Oncol; 2010 Feb; 28(4):675-82. PubMed ID: 19841329
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.
Tuffaha HW; Mitchell A; Ward RL; Connelly L; Butler JRG; Norris S; Scuffham PA
Genet Med; 2018 Sep; 20(9):985-994. PubMed ID: 29300376
[TBL] [Abstract][Full Text] [Related]
9. Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral.
Lieberman S; Tomer A; Ben-Chetrit A; Olsha O; Strano S; Beeri R; Koka S; Fridman H; Djemal K; Glick I; Zalut T; Segev S; Sklair M; Kaufman B; Lahad A; Raz A; Levy-Lahad E
Genet Med; 2017 Jul; 19(7):754-762. PubMed ID: 27929526
[TBL] [Abstract][Full Text] [Related]
10. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
11. BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
Kwon JS; Tinker AV; Hanley GE; Pansegrau G; Sun S; Carey MS; Schrader I
Gynecol Oncol; 2019 Mar; 152(3):459-464. PubMed ID: 30876489
[TBL] [Abstract][Full Text] [Related]
12. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review.
Koldehoff A; Danner M; Civello D; Rhiem K; Stock S; Müller D
Value Health; 2021 Feb; 24(2):303-312. PubMed ID: 33518037
[TBL] [Abstract][Full Text] [Related]
14. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
Manchanda R; Loggenberg K; Sanderson S; Burnell M; Wardle J; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; McGuire A; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):379. PubMed ID: 25435541
[TBL] [Abstract][Full Text] [Related]
15. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
16. Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities.
Augustyn AM; Agostino NM; Namey TL; Nair S; Martino MA
Breast Cancer Res Treat; 2011 Sep; 129(2):629-34. PubMed ID: 21607582
[TBL] [Abstract][Full Text] [Related]
17. BRCA genetic testing of individuals from families with low prevalence of cancer: experiences of carriers and implications for population screening.
Shkedi-Rafid S; Gabai-Kapara E; Grinshpun-Cohen J; Levy-Lahad E
Genet Med; 2012 Jul; 14(7):688-94. PubMed ID: 22481128
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
Manchanda R; Patel S; Antoniou AC; Levy-Lahad E; Turnbull C; Evans DG; Hopper JL; Macinnis RJ; Menon U; Jacobs I; Legood R
Am J Obstet Gynecol; 2017 Nov; 217(5):578.e1-578.e12. PubMed ID: 28690137
[TBL] [Abstract][Full Text] [Related]
19. Expanding the criteria for BRCA mutation testing in breast cancer survivors.
Kwon JS; Gutierrez-Barrera AM; Young D; Sun CC; Daniels MS; Lu KH; Arun B
J Clin Oncol; 2010 Sep; 28(27):4214-20. PubMed ID: 20733129
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
